SLC5A2 and heart failure: Furthermore, the DECLARE TIMI 58 trial demonstrated that the SGLT2 inhibitor dapagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure in comparison to a matching placebo in patients with type 2 diabetes and either a high cardiovascular risk or established atherosclerotic cardiovascular disease (10) (Table 1).